View All Upcoming Sponsored Webinars
May 12, 201611 am to 12 pm EDT
Cancer regimen-related toxicities are often devastating consequences of current chemo- and radiotherapy regimens used for the treatment of malignancies. But not all patients are at equal risk for developing toxicities and, for those who do, the response to specific treatment varies. Risk and response are largely determined by genomic and epigenomic profiles. This symposium will discuss regimen-related toxicities and present examples of how the application of genomics (and epigenomics) can be applied to effectively identify and treat patients at risk.
Stephen T. Sonis, D.M.D., D.M.Sc.
Founder, Partner, Chief Scientific Officer
Dr. Sonis is a world-renowned expert in epithelial injury associated with cancer therapy. His development of predictive animal models has enabled the investigation of the biological basis of mucositis and has assisted in the development of potential therapies. The results of his studies on the molecular and cellular pathogenesis of mucositis have established the basis of the mechanistic paradigm for mucosal injury. Dr. Sonis’ interest in the genomic basis for toxicity risk and its pathology has led to innovative genomics-based analytical approaches to clinically actionable outcomes to personalize disease therapy. These studies have resulted in the identification of drug and toxicity specific SNP and gene networks which identify individuals at risk of treatment toxicities and define the genomic parameters which differentiate patients who respond to a specific drug treatment from those who do not.
Dr. Sonis has published extensively on the clinical, biological, and health economic aspects of cancer and complications associated with its treatment. He is the author of over 200 original publications, reviews and chapters, 10 books, and 5 patents. Dr. Sonis has obtained degrees from Tufts University and Harvard University and completed his post-doctoral education (tumor immunology) at Oxford University. He holds appointments at the Harvard School of Dental Medicine (Clinical Professor of Oral Medicine, Department of Oral Medicine, Infection and Immunity), the Dana-Farber Cancer Institute and Brigham and Women’s Hospital where he is Division Chief and Senior Surgeon.
250 First Avenue, Suite 300
Needham, MA 02494
Biological Therapeutic Products
Biomarkers & Diagnostics
Bioprocess & Manufacturing
Clinical Trials & Translational Medicine
Drug & Device Safety
Drug Discovery & Development
IT & Informatics
Technology & Tools For Life Science
Cambridge Healthtech Institute
Cambridge Innovation Institute